CD70 UCAR T cells Therapy (Nanjing Calmhome Cell and Gene Engineering Institute)
- Generic Name
- CD70 UCAR T cells Therapy (Nanjing Calmhome Cell and Gene Engineering Institute)
A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies
Phase 1
Recruiting
- Conditions
- Peripheral T-cell LymphomaCutaneous T-cell Lymphoma (CTCL)NHL (Non-Hodgkin Lymphoma)
- Interventions
- First Posted Date
- 2025-04-06
- Last Posted Date
- 2025-04-06
- Target Recruit Count
- 24
- Registration Number
- NCT06914037
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China
A Clinical Study of CHT101 in CD70-Positive Advanced Solid Tumors
- First Posted Date
- 2024-12-12
- Last Posted Date
- 2024-12-12
- Target Recruit Count
- 36
- Registration Number
- NCT06730659
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors
Phase 1
Not yet recruiting
- Conditions
- Advanced Solid TumorMetastatic TumorRenal Cell CarcinomaNasopharyngeal CarcinomaOvarian CancerCervix CancerHead and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2024-04-25
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Zhejiang University
- Target Recruit Count
- 18
- Registration Number
- NCT06383507
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath